About Proteus Digital Health
Armed with more than 300 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category that measures medication effectiveness and helps physicians improve treatment outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs.
26 April, 2016
FDA Issues Complete Response Letter for Digital Medicine New Drug Application
TOKYO, JAPAN and REDWOOD SHORES, CALIF. – April 26, 2016 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response ...Read moreRead more
15 April, 2016
Proteus Digital Health Raises Additional $50 Million in Equity Financing
REDWOOD CITY, CALIF. – April 15, 2016 – Leading Digital Medicine company Proteus Digital Health announced today it has secured $50 million in Series H financing. This investment further strengthens the company’s balance sheet and provides ...Read moreRead more
4 April, 2016
Proteus Digital Health Presents Interim Results at ACC From a Randomized Controlled Clinical Study of Proteus Discover
Digital Medicines Study Demonstrates Patients Benefit from Feedback on Medication Adherence and Behavior Patterns APRIL 04, 2016 – CHICAGO, IL – Proteus Digital Health presented interim results from a randomized controlled study of Proteus ...Read moreRead more
27 January, 2016
The next level of on-demand expert medical care is here: USC Center for Body Computing announces its Virtual Care Clinic (VCC) in collaboration with eight strategic partners for an ‘anytime, anywhere’ disruptive health care model to deliver borderless health care
Innovative digital health solution uses mobile apps, wearable sensors, virtual human health care providers, augmented and virtual reality (AR/VR), data collection, analytics and artificial intelligence using digital communication tools to ...Read moreRead more
11 January, 2016
Barton Health First to Implement Proteus Digital Health’s Innovative Solution for Patients with Chronic Conditions
JANUARY 11, 2016 – REDWOOD CITY, and SOUTH LAKE TAHOE, CA—Barton Health is the first health system to implement Proteus Discover, a Digital Medicine offering that activates patients and enables rapid assessment and personalized treatment ...Read moreRead more
17 November, 2015
Proteus Digital Health Announces New Chairman of the Board and Chief Commercial Officer
Leading Digital Medicines Company Strengthens Customer and Corporate Governance Capabilities to Advance Commercialization NOVEMBER 17, 2015, REDWOOD CITY, CA—Proteus Digital Health™ announced three executive appointments in order to propel the ...Read moreRead more
10 September, 2015
U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health
The first Digital Medicine, a drug/device product, combines Otsuka’s ABILIFY® (aripiprazole) for serious mental illness, embedded with the Proteus® ingestible sensor in a single tablet to digitally record ingestion and, with patient consent, ...Read moreRead more
2 July, 2015
First Medical Device Cleared by FDA With Adherence Claim
REDWOOD SHORES, CALIF. Proteus Digital Health, Inc. today announced that the FDA has expanded the Indications for Use statement for the latest generation of its Ingestible Sensor technology, enabling the device to be used as an aid in the ...Read moreRead more
12 January, 2015
Oracle and Proteus Integrate Proteus Digital Health Feedback System with Oracle Health Sciences InForm to Help Increase Clinical Trial Accuracy
Oracle Health Sciences InForm electronic data capture platform utilizes Proteus solution, enabling greater accuracy in measuring medication adherence during clinical trials REDWOOD SHORES News Summary Highly engaged patients that consistently ...Read moreRead more
29 July, 2014
Proteus Digital Health™ Continues to Build Momentum, Most Recent Round of Funding Reaches over $172MM
REDWOOD CITY, CA — Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional ...Read moreRead more
28 July, 2014
Proteus Digital Health Prevails in Trademark Infringement Case
REDWOOD CITY, Calif., (August 1, 2014) -– Proteus® Digital Health, a leading digital medicines company, today announced that it has entered into an agreement settling its claims against Texas-based Proteus Biomedical LLC for trademark ...Read moreRead more
2 June, 2014
Proteus Digital Health™ Raises $120 million, Strengthens Financial Management and Governance Expertise through Key Executive Appointments
Steve Fieler joins as Chief Financial Officer, completing the company’s executive team Jonathan Symonds, former CFO of Novartis AG, appointed to Board of Directors REDWOOD CITY, CA—Leading digital medicines company Proteus Digital Health™ raised ...Read moreRead more
16 April, 2014
Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network
REDWOOD CITY, Calif. — Proteus Digital Health (TM), a leading digital medicines company, today announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology ...Read moreRead more
10 March, 2014
Proteus Digital Health™, NHS England and UK Trade & Investment to Bring Transformative Digital Health Technology to the UK
LONDON, ENGLAND— Leading digital medicines company Proteus Digital Health™ is partnering with Eastern Academic Health Science Network (EAHSN), The Northern Health Science Alliance (NHSA) and Oxford University, Oxford University Hospitals NHS ...Read moreRead more
1 May, 2013
Oracle Invests in Proteus Digital Health and its FDA-Approved Ingestible Sensor Platform
Digital Health Feedback System Will Allow Oracle’s Clinical Trial Applications Customers Exclusive Access to Real-time Data on Therapeutic Use to Dramatically Improve Clinical Trial Efficiency Redwood Shores, CA – May 1, 2013 News Facts Oracle ...Read moreRead more
1 May, 2013
Proteus Digital Health Completes $62.5 Million Financing
Proceeds to Advance Development of Digital Medicine Products Redwood City, Calif. – May 1, 2013 Proteus Digital Health, Inc announced today that the company has completed a second closing of its Series F financing, raising $62.5 million in ...Read moreRead more
7 January, 2013
Proteus Digital Health Expands Commercial Team and Board of Directors to Drive Commercial Growth
REDWOOD CITY, Calif. – January 7, 2013 Proteus Digital Health Inc. announced today the expansion of the company’s executive team and board of directors with the addition of three healthcare leaders to drive its commercial strategy as the company ...Read moreRead more
30 July, 2012
Proteus Digital Health Announces FDA Clearance of Ingestible Sensor
REDWOOD CITY, Calif. – July 30, 2012 – Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to ...Read moreRead more
5 July, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
REDWOOD CITY, CA, and TOKYO, JAPAN, July 5, 2012 – Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new ...Read moreRead more
31 January, 2012
Proteus Announces Issuance of U.S. Patent for Digital Health Communications
Proteus Biomedical Inc., a pioneer in digital health, announced today that the United States Patent Office will award U.S. Patent Number 8114021 to Proteus. The patent, entitled “Body Associated Receiver and Method,” is directed to the Proteus ...Read moreRead more
13 January, 2012
Lloydspharmacy partners with Proteus Biomedical to launch innovative digital health product
UK community pharmacy chain Lloydspharmacy and US company Proteus Biomedical, Inc., a pioneer in digital health, have today announced an exclusive strategic collaboration to commercialize and launch Helius™, a digital health product focused on ...Read moreRead more
15 September, 2011
Chris Brinsmead Appointed Chairman of Proteus Biomedical Europe
2012 UK Launch of First Commercial Product Planned Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Chris Brinsmead has joined the company as Chairman, Proteus Biomedical Europe. Brinsmead has over 30 years of ...Read moreRead more
14 July, 2011
Proteus Announces Issuance of U.S. Patent for Ingestible Digital Devices
Technology to Become a Foundation for mHealth Products and Services Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the United States Patent Office awarded U.S. Patent Number 7,978,064 to Proteus. The patent, ...Read moreRead more
7 June, 2011
Avery Dennison Medical Solutions and Proteus Biomedical Launch Partnership
Development, License and Manufacturing Agreements Focus on Wearable Sensor Technology Avery Dennison Medical Solutions, a division of Avery Dennison Corporation (NYSE: AVY) and a global leader in pressure-sensitive adhesive technologies for ...Read moreRead more
13 August, 2010
Proteus Biomedical Announces European CE Mark Approval of Ingestible Sensor and Monitor System
Company Also Announces Creation of User Experience Group with Former IDEO Leader Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that it has received CE Mark approval to market its ingestible sensor and personal ...Read moreRead more
21 April, 2010
Proteus Announces FDA Clearance of Wireless Personal Health Monitor
Company Also Completes Financing with Leading Medical Device, Pharmaceutical and Semiconductor Companies as Investors Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that it has received 510(k) clearance from the US ...Read moreRead more
12 January, 2010
Proteus Biomedical Announces License and Collaboration Agreement for Sensor-Based Pharmaceuticals
Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based ...Read moreRead more
9 June, 2009
Proteus Biomedical Announces Appointment of David Lawrence as Director
Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that David Lawrence, M.D. has been appointed to serve on its pharmaceutical systems divisional Board of Directors. Dr. Lawrence joins a distinguished group of ...Read moreRead more
4 December, 2008
Proteus Biomedical Honored by World Economic Forum
Technology Pioneer Award Recognizes Potential of Intelligent Medicine to Improve Business and Society Redwood City, Calif. – Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has been selected a 2009 ...Read moreRead more
15 October, 2008
Proteus Biomedical Raises $32 Million in Series D Funding
Proceeds to Advance Development of Intelligent Medicine Products Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has raised $32 million in a series D equity financing. New corporate investors ...Read moreRead more
24 April, 2008
Proteus Biomedical Initiates Clinical Study of Novel Technology for Heart Failure
Study To Assess Feasibility of First Application of Company’s Proprietary Platform Technology to Improve Myocardial Efficiency Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today the initiation of the RETIME 2.0 ...Read moreRead more
7 January, 2008
Proteus Biomedical Announces Appointment of Independent Directors
Accelerates Expansion of Pharmaceutical, Hospital Businesses Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Ms. Ginger Graham and Ms. Kathy Murray have been appointed to serve on its divisional Boards of ...Read moreRead more
Meet our Executive Team
Andrew ThompsonCo-Founder, CEO
George Savage, M.D.Co-Founder, CMO
Mark Zdeblick, Ph.D.Co-Founder, Chief Technologist
Steve FielerChief Financial Officer
Molly O'NeillChief Commercial Officer
David O'ReillyChief Product Officer
Sean HandelHead of Product Management & Design
Neela PaykelHead of Legal Affairs and Compliance
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets.
Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health. His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket.
Andrew serves on the World Economic Forum Technology Pioneers selection committee and he is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform. Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies.
He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley.
George Savage, M.D.
George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development.
Named by PharmaVoice as one of the 100 most inspiring people in the pharmaceutical industry, his focus is on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’ ingestible sensor platform.
Dr. Savage holds a B.S. in biomedical engineering from Boston University, an M.D. from Tufts University School of Medicine and an M.B.A. from Stanford University Graduate School of Business
Mark Zdeblick, Ph.D.
Co-Founder, Chief Technologist
Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems.
Mark holds a B.S. in civil engineering and a B.A. in architecture, both from the University of Illinois, and an M.S. in aeronautics and astronautics and Ph.D. in electrical engineering from Stanford University.
Chief Financial Officer
Steve Fieler is chief financial officer of Proteus Digital Health. Prior to joining Proteus, he was chief financial officer for Hewlett Packard’s software division, a business with $4 billion in annual revenue.
Steve was previously HP’s vice president investor relations and held several other leadership positions in corporate development and operations at the company.
Steve holds a BA in Economics and International Relations from Brown University and an MBA from Harvard Business School.
Chief Commercial Officer
Molly O’Neill is chief commercial officer of Proteus Digital Health, where she leads partnerships with major health systems, payers and key provider customers. Molly is a healthcare industry veteran with a 30+ year track record of developing and executing growth strategies to increase market share and revenues. Prior to joining Proteus, she was the Senior Vice President of business development at Tenet Healthcare, a diversified healthcare services company. Having worked across major provider and healthcare service companies, Molly believes the greatest potential of Digital Medicines is in transforming a patient’s engagement with their physicians, their families and most importantly their own health.
Molly has held leadership roles at Duke Medicine, Partners Healthcare, Inova Health System, Ascension Health Care Network, a joint venture between AscensionHealth Alliance and Oak Hill Capital Partners. Molly is a member of the board of World Care International Inc. and holds degrees from the Medical College of Virginia and Virginia Commonwealth University.
Chief Product Officer
David O’Reilly is chief product officer of Proteus Digital Health and leads the company’s product development, manufacturing, business development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to health care and biotechnology companies at L.E.K. Consulting.
David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.
Head of Product Management & Design
Sean Handel is head of product management and design at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.
Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.
Head of Legal Affairs and Compliance
Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues. Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield.
Neela is a graduate of Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University.
Meet our Board of Directors
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets
Jonathan Symonds, CBE
Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England.
Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc.
Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman.
Shumeet Banerji, Ph.D.
Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.
Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. and Innocoll, AG.
Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.
Robert Epstein, M.D., M.S.
Dr. Robert Epstein was most recently president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.
Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and has served on the Board of Directors of the Drug Information Association.
He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.
Frank Fischer has more than 25 years of senior management experience in the medical device industry.
The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.
Frank continues to serve on the boards of several privately held medical device companies.
Alan J. Levy, Ph.D.
Alan Levy is a venture partner with Frazier Healthcare Ventures and has over 30 years of senior management experience in the medical device industry.
He serves on the board of Intuitive Surgical, a publicly held company, and several other privately held medical device firms.
Myrtle is CEO of Myrtle Potter and Company. A best-selling author, Myrtle has dedicated three decades to serving the healthcare needs of millions of consumers.
She serves on the board of Everyday Health, Liberty Mutual and is on the board of Trustees of the University of Chicago. Myrtle was president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.
Ryan Schwarz is a managing director at The Carlyle Group where he leads the healthcare investing practice for the company’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.
Ryan serves on the boards of AcuFocus, Lipsonix, NeoVista, Cellutions and PixelOptics.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.
Previously, Charles ran corporate strategy for Microsoft and focused on partnering and M&A.
Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.
With over 15 years of experience in operations and venture capital, he currently serves on the boards of CBR Systems, Acura Pharmaceuticals, Clear Vascular, Medlogics, and Sound ID.
We have engaged license agreements with strategic partners to build our patented ingestible-sensor technology into new Digital Medicine offerings.
Otsuka and Proteus are partnering to combine Otsuka’s ABILIFY® (aripiprazole) with the FDA cleared Proteus® ingestible sensor embedded in a single tablet at point of manufacture. This is the first time the FDA cleared Proteus® ingestible sensor will be integrated with an approved medication as a combination product to measure medication-taking patterns and physiologic response.
Proteus has had a strategic partnership with Novartis since 2009.